Impax v. Qilu Pharmaceutical: RYTARY Patent Dispute Settled in 126 Days
Impax Laboratories filed suit against Qilu Pharmaceutical in the District of New Jersey, asserting five patents covering its RYTARY (Carbidopa/Levodopa) extended-release capsule formulations across four dosage strengths. The action was administratively terminated after the parties reported a settlement, closing the case in just 126 days.
Five-Patent RYTARY Infringement Dispute Resolved Swiftly by Settlement
On March 19, 2025, Impax Laboratories, LLC filed a patent infringement action in the U.S. District Court for the District of New Jersey against Qilu Pharmaceutical Co., Ltd., a China-based generic drug manufacturer. The complaint asserted five U.S. patents — US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2 — all directed at the formulation and delivery technology underlying RYTARY, Impax’s branded extended-release carbidopa/levodopa capsules used in the management of Parkinson’s disease.
The case was administratively terminated on July 23, 2025, after the parties reported to the court that a settlement had been reached. The court’s order does not constitute a formal dismissal under the Federal Rules of Civil Procedure; instead, the parties have 60 days to file dismissal papers. If no such papers are filed, the court will dismiss with prejudice and without costs. The precise financial or licensing terms of the settlement have not been disclosed in the public record.
Resolution in 126 days is notably swift for Hatch-Waxman ANDA litigation, where cases routinely extend two to four years. The speed suggests the parties may have reached a licensing or market-entry agreement relatively early in proceedings, potentially before significant discovery costs were incurred. Whether Qilu received a royalty-bearing licence or agreed to a delayed market-entry date remains unknown from public filings.
Filing to Case Terminated in 126 days
126 days — faster than the typical ANDA patent litigation timeline of 2–4 years
Administrative termination following settlement: what the order means
Administrative termination is not a final dismissal
The court’s July 23 order administratively terminates the action but explicitly states it does not constitute a dismissal under the Federal Rules of Civil Procedure. The parties have 60 days to file formal dismissal papers. If they fail to do so, the court will dismiss with prejudice and without costs automatically. This is a standard NJ District Court settlement management mechanism — not a merits ruling.
No merits adjudicationImpax preserves its RYTARY exclusivity position
By settling before any claim construction or invalidity ruling, Impax avoids the risk of an adverse judgment that could weaken its patent portfolio across all five asserted patents. A settlement typically allows the brand holder to negotiate the terms of any generic market entry — such as a delayed launch date — preserving revenue from RYTARY while resolving litigation costs. The patents themselves remain intact and enforceable against other potential ANDA filers.
Patents remain enforceableQilu avoids adverse ruling but outcome terms are undisclosed
Qilu exits litigation without a final court determination on infringement or validity. In ANDA litigation, this typically means the generic challenger either agreed to a specific launch date, accepted a licensing arrangement, or both. Absent a successful invalidity ruling, Qilu cannot launch at-risk without exposing itself to contempt or re-litigation. The undisclosed settlement terms are the key commercial variable that will determine Qilu’s market-entry timeline.
Launch timing undisclosedOther generic filers face the same five-patent barrier
Because the settlement produced no invalidity or non-infringement finding, all five RYTARY patents remain valid and enforceable. Any other generic manufacturer holding or seeking an ANDA for carbidopa/levodopa extended-release capsules will need to address the same patent estate. The outcome raises the cost-benefit calculus for competing ANDA challengers, as Impax has demonstrated a willingness to litigate and negotiate rather than grant open licences.
Patent estate intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Impax Laboratories, LLC | Company | Pharmaceutical company — holder of RYTARY (Carbidopa/Levodopa) extended-release capsule patentsSearch in Eureka ↗ |
| Defendant | Qilu Pharmaceutical Co., Ltd. | Company | Qilu Pharmaceutical Co., Ltd. — China-based generic drug manufacturer and ANDA applicantSearch in Eureka ↗ |
| Plaintiff counsel | Stephanie L. Jonaitis | Attorney | Counsel for Impax Laboratories, LLCSearch in Eureka ↗ |
| Plaintiff law firm | TROUTMAN PEPPER LOCKE LLP | Law Firm | Representing Impax Laboratories, LLCSearch in Eureka ↗ |
| Defendant counsel | Ian Scott | Attorney | Counsel for Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Taft, Stettinius & Hollister LLP | Law Firm | Representing Qilu Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s administrative termination order is procedurally distinct from a standard dismissal: it preserves the court’s jurisdiction for 60 days while the parties finalise settlement documentation. The explicit statement that the order ‘shall not constitute a dismissal Order under the Federal Rules of Civil Procedure’ is significant — it means no final judgment has been entered, no claim has been adjudicated on the merits, and the case can technically be reopened if settlement terms break down before formal dismissal papers are filed.
US8557283B2 — RYTARY Extended-Release Carbidopa/Levodopa Formulations
The five patents asserted — US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2 — collectively protect the formulation science underlying RYTARY, Impax’s extended-release carbidopa/levodopa capsules approved for Parkinson’s disease, post-encephalitic parkinsonism, and related conditions. The patents span application dates from 2012 through 2015, suggesting a continuation-based prosecution strategy designed to extend protection across the full commercial life of the product.
The multi-patent estate covering a single FDA-approved product is a well-established brand-protection strategy in pharmaceutical IP. Each patent in the family may claim distinct aspects — such as specific bead formulations, coating technologies, release profiles, or dosage strengths — making it difficult for a generic challenger to design around one patent without implicating others. For the carbidopa/levodopa market, which serves a large and growing Parkinson’s patient population, the commercial stakes of delayed generic entry are significant for both innovator revenue and healthcare cost pressure.
Should your R&D team run an FTO against the RYTARY patent family?
Any company developing or pursuing an ANDA for extended-release carbidopa/levodopa capsules — particularly at the four dosage strengths specified in RYTARY’s label — should treat this five-patent family as a primary FTO target. The unresolved settlement means no claim has been invalidated, and all five patents remain active Orange Book listings. Product formulators working on modified-release levodopa delivery systems should also assess whether their bead or coating approaches implicate claim scope in US9463246B2 or US9089608B2.
PatSnap Eureka’s FTO Search Agent can map each of the five asserted patents against your proposed formulation, identify relevant prior art that was not cited during prosecution, and flag continuation relationships that may extend the risk horizon beyond the earliest expiry. Eureka’s claim charting tools allow your patent counsel to assess infringement risk at the claim level before committing to costly ANDA preparation and filing.
Run a freedom-to-operate analysis on US8557283B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent disputes in carbidopa/levodopa and CNS drug formulations
Explore comparable Hatch-Waxman infringement actions in the NJ District Court involving extended-release CNS drug formulations and multi-patent brand protection strategies.
What this case signals for the Parkinson’s drug formulation IP landscape
A five-patent infringement suit settled in 126 days sends clear signals about enforcement posture and generic market-entry risk in the carbidopa/levodopa space.
Early settlement preserves patent validity across the full RYTARY portfolio
With no claim construction or invalidity ruling on record, all five RYTARY patents survive the Qilu challenge legally unscathed. Companies holding ANDA positions on carbidopa/levodopa extended-release formulations must now weigh litigation risk against the same intact patent estate.
126-day resolution is a strong signal of pre-litigation licensing leverage
Cases this short in Hatch-Waxman litigation typically indicate either pre-existing settlement negotiations or early agreement on market-entry terms. Impax’s willingness to file and quickly resolve suggests a robust licensing programme rather than a ‘block all comers’ strategy — worth noting for any company evaluating ANDA filings.
Impax v Qilu — key questions answered
Impax asserted five patents: US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2. All five relate to the formulation technology underlying RYTARY (Carbidopa/Levodopa) extended-release capsules for oral use, covering four dosage strengths from 23.75 mg/95 mg to 61.25 mg/245 mg.
The court’s July 23, 2025 order administratively terminates the action following a reported settlement but explicitly states it is not a dismissal under the Federal Rules of Civil Procedure. The parties have 60 days to file formal dismissal papers. If no papers are filed, the court will dismiss with prejudice and without costs automatically. No merits determination was made.
No. The case settled before any claim construction hearing, invalidity ruling, or infringement finding. All five asserted patents — US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2 — remain valid and enforceable. The settlement produced no public record of any adverse patent determination.
The case was filed on March 19, 2025 and administratively terminated on July 23, 2025 — a span of 126 days. This is notably faster than the typical Hatch-Waxman ANDA litigation timeline of two to four years, suggesting the parties reached settlement terms relatively early in the proceedings, likely before significant discovery or motion practice.
Because no patent was invalidated or found non-infringed, all five RYTARY patents remain Orange Book-listed barriers for any subsequent ANDA applicant. Companies developing generic carbidopa/levodopa extended-release capsules must independently address each patent through paragraph IV certifications and, if challenged, litigation. The intact patent family also means IPR petitions remain a potential but costly avenue for challenging validity.
PatSnap Eureka searches patents and litigation data to answer instantly.